Genetics and Personalized Medicine-a Role in Statin Therapy?
Patel J, Abd T, Blumenthal RS, et al.
Curr Atheroscler Rep. 2014 Jan;16(1):384.
Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Kassogue Y, Quachouh M, Dehbi H, et al.
Med Oncol. 2014 Jan;31(1):782. Epub 2013 Nov 29.
Gene-Wide Tagging Study of the Association Between KCNT1 Polymorphisms and the Susceptibility and Efficacy of Genetic Generalized Epilepsy in Chinese Population.
Qu J, Zhang Y, Yang ZQ, et al.
CNS Neurosci Ther. 2013 Nov 27. [Epub ahead of print]
Genetics of antipsychotic-induced weight gain: update and current perspectives.
Kao AC, Müller DJ.
Pharmacogenomics. 2013 Dec;14(16):2067-83.
Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset.
Gordon AS, Tabor HK, Johnson AD, et al.
Hum Mol Genet. 2013 Nov 28. [Epub ahead of print]
Pyrosequencing for Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Isolates and Clinical Specimens.
Lin SY, Rodwell TC, Victor TC, et al.
J Clin Microbiol. 2013 Nov 27. [Epub ahead of print]
Clinical Implementation of Genetic Testing in Medicine: A US Regulatory Science Perspective.
Lesko LJ, Schmidt SA.
Br J Clin Pharmacol. 2013 Nov 29. [Epub ahead of print]
Molecular Pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P, Jonkers J.
Clin Cancer Res. 2013 2013 Nov 22. [Epub ahead of print]
Antidepressant pharmacogenetics.
Singh AB, Bousman CA, Ng C, Berk M.
Curr Opin Psychiatry. 2014 Jan;27(1):43-51.
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Dienstmann R, Rodon J, Prat A, et al.
Ann Oncol. 2013 Nov 20. [Epub ahead of print]
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
de Keyser CE, Peters BJ, Becker ML, et al.
Pharmacogenet Genomics. 2013 Nov 20. [Epub ahead of print]
Molecular phenotypes in triple negative breast cancer from african american patients suggest targets for therapy.
Lindner R, Sullivan C, Offor O, et al.
PLoS One. 2013 Nov 18;8(11):e71915.
ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment.
Lau C, Killian KJ, Samuels Y, Rudloff U.
Methods Mol Biol. 2014;1102:461-80.
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response.
Hodgson K, Tansey K, Dernovsek MZ, et al.
J Psychopharmacol. 2013 Nov 20. [Epub ahead of print]
P38 MAPK Contributes to Resistance and Invasiveness of HER2-Overexpressing Breast Cancer.
Donnelly SM, Paplomata E, Peake BM, et al.
Curr Med Chem. 2013 Nov 19. [Epub ahead of print]